Clinical Trial Update: To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of adding vildagliptin to sulfonylurea in adults with type 2 diabetes inadequately controlled on sulfonylurea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED